SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

Search

BioMerieux

Fermé

SecteurSoins de santé

115.5 1.49

Résumé

Variation du prix de l'action

24h

Actuel

Min

113.8

Max

115.8

Chiffres clés

By Trading Economics

Revenu

215M

Ventes

785M

P/E

Moyenne du Secteur

31.236

57.333

Rendement du dividende

0.79

Marge bénéficiaire

11.32

Employés

14,147

EBITDA

161M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+16.61% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.79%

2.63%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-117M

13B

Ouverture précédente

114.01

Clôture précédente

115.5

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

BioMerieux Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 avr. 2025, 08:49 UTC

Principaux Mouvements du Marché

BioMerieux Shares Fall After Warning on Currency-Exchange Hit

Comparaison

Variation de prix

BioMerieux prévision

Objectif de Prix

By TipRanks

16.61% hausse

Prévisions sur 12 Mois

Moyen 133.17 EUR  16.61%

Haut 140 EUR

Bas 127 EUR

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

6

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

113.8 / 118.9Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.